More on Amgen (AMGN): Q4 missed on the bottom line but revenue beat on a solid 11% jump in total sales. Net earnings fell 16% Y/Y, hurt by acquisition-related expenses and higher operating costs. Revenue growth was due to strong sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, which more than doubled from a year earlier. Prolia, a treatment for osteoporosis, also saw sales more than double Y/Y, with 40% sales growth over Q3. Shares +0.7% AH.